Oraluck PattanaprateepAtiporn IngsathitMark McEvoyJohn AttiaAmmarin ThakkinstianFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityUniversity of Newcastle, AustraliaHunter Medical Research Institute New Lambton Heights2019-08-232019-08-232018-05-01Value in Health Regional Issues. Vol.15, (2018), 155-16022121102221210992-s2.0-85046802610https://repository.li.mahidol.ac.th/handle/20.500.14594/45759© 2018 Objectives: To assess the cost effectiveness of renin-angiotensin aldosterone system (RAAS) blockade in the progression of chronic kidney disease using Thai clinical data in 2014. Methods: A Markov model for cost-effectiveness analysis was applied to estimate from a societal perspective the cost per quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio of RAAS versus non-RAAS used in preventing the progression of end-stage renal disease and death stratified by diabetic and nondiabetic patients. Input parameters related to clinical outcomes were obtained from a cohort study of treatment effectiveness, whereas costs were retrieved from the Ramathibodi Hospital electronic database in 2015 and the Health Intervention and Technology Assessment Program in Thailand. One-way analysis and probabilistic sensitivity analysis were performed to evaluate uncertainty surrounding model parameters. Results: From the model, using RAAS improved QALY from 2.41 to 3.16 years and from 2.37 to 3.20 years in diabetic and nondiabetic groups, respectively. The incremental cost-effectiveness ratios for these groups were 78,250 baht (US $2,353.39) and 66,674 baht (US $2,005.22), respectively. Conclusions: Using RAAS in patients with chronic kidney disease improved QALY in both diabetic and nondiabetic patients and proved to be cost-effective.Mahidol UniversityEconomics, Econometrics and FinanceMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1016/j.vhri.2017.12.011